PharmaCyte Biotech, Inc. (PMCB)
Automate Your Wheel Strategy on PMCB
With Tiblio's Option Bot, you can configure your own wheel strategy including PMCB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PMCB
- Rev/Share 0.0
- Book/Share 6.4145
- PB 0.1793
- Debt/Equity 0.0
- CurrentRatio 18.0102
- ROIC -0.0898
- MktCap 7815146.0
- FreeCF/Share -0.6767
- PFCF -1.6993
- PE -6.9436
- Debt/Assets 0.0
- DivYield 0
- ROE -0.0251
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
Published: November 25, 2025 by: Business Wire
Sentiment: Neutral
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company's strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 202.
Read More
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
Published: September 02, 2025 by: Business Wire
Sentiment: Neutral
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, “TNF”) by an additional $3 million. The Company does so to help support TNF's recent acquisition of a license with LightSolver, Ltd. (“LightSolver”), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing accelerator designed.
Read More
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
Published: August 20, 2025 by: Business Wire
Sentiment: Neutral
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Company's most recent 10K. With the addition of the $7 million in proceeds from this financing, the Company's balance sheet has been further strengthened, providing significant finan.
Read More
About PharmaCyte Biotech, Inc. (PMCB)
- IPO Date 2013-01-02
- Website https://pharmacyte.com
- Industry Biotechnology
- CEO Joshua N. Silverman
- Employees 2